In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes from the trial. John Strickler from Duke University then provides 32 month follow-up data from the MOUNTAINEER trial of tucatinib and trastuzumab in HER2+ colorectal cancer. Additionally, listen to insightful perspectives from Major Lee, The University of Pennsylvania, and David Tougeron, Poitiers University Hospital, on practice changing trials in colorectal cancer.